Important Rating: Hutchison China Meditech Ltd (LON:HCM) Stock Rating Reiterated by Panmure Gordon; The GBX 2630.00 Target Indicates 38.24% Potential

November 23, 2016 - By Winifred Garcia

Hutchison China Meditech Ltd (LON:HCM) Rating

London: In an analyst note revealed to clients and investors on Wednesday morning, Panmure Gordon kept their “Buy” rating on shares of Hutchison China Meditech Ltd (LON:HCM). They currently have a GBX 2630.00 TP on the company. Panmure Gordon’s target indicates a potential upside of 38.24% from the company’s previous stock close.

Hutchison China MediTech Limited (LON:HCM) Ratings Coverage

Out of 2 analysts covering Hutchison China Meditech Ltd (LON:HCM), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. GBX 2630 is the highest target while GBX 1750 is the lowest. The GBX 2630 average target is 39.89% above today’s (GBX 1880) stock price. Hutchison China Meditech Ltd has been the topic of 17 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The company was maintained on Tuesday, July 28 by Panmure Gordon. The stock of Hutchison China MediTech Limited (LON:HCM) earned “Buy” rating by Beaufort Securities on Monday, December 21. As per Wednesday, December 9, the company rating was maintained by Beaufort Securities. The rating was reinitiated by Panmure Gordon with “Buy” on Friday, September 16. The stock of Hutchison China MediTech Limited (LON:HCM) earned “Buy” rating by Beaufort Securities on Tuesday, November 1. The company was maintained on Wednesday, April 13 by Beaufort Securities. As per Monday, November 2, the company rating was maintained by Beaufort Securities. Panmure Gordon maintained the shares of HCM in a report on Monday, October 31 with “Buy” rating. As per Wednesday, August 3, the company rating was maintained by Beaufort Securities. The company was maintained on Monday, May 16 by Beaufort Securities.

About 5,336 shares traded hands. Hutchison China MediTech Limited (LON:HCM) has risen 4.54% since April 22, 2016 and is uptrending. It has underperformed by 0.79% the S&P500.

Hutchison China MediTech Limited is a China-based, globally-focused healthcare group. The company has a market cap of 1.13 billion GBP. The Firm researches, develops, makes and sells pharmaceuticals and health-related consumer products. It currently has negative earnings. The Company’s Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

According to Zacks Investment Research, “Hutchison China MediTech Limited researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. The Company offers drugs for oncology and autoimmune diseases treatment. Hutchison China MediTech Limited is based in Hong Kong.”

More notable recent Hutchison China MediTech Limited (LON:HCM) news were published by: Prnewswire.com which released: “Chi-Med webcast presentation now available for on-demand viewing: Deutsche …” on November 21, 2016, also Nasdaq.com with their article: “Hutchison China MediTech Limited (HCM), Interview with Christian Hogg …” published on April 07, 2016, Marketwatch.com published: “Hutchison China MediTech Ltd. ADR” on August 17, 2009. More interesting news about Hutchison China MediTech Limited (LON:HCM) were released by: Businesswire.com and their article: “Hutchison China MediTech Limited Announces Pricing of U.S. Public Offering of ADSs” published on March 17, 2016 as well as Seekingalpha.com‘s news article titled: “Hutchison China MediTech IPO: Consider A Modest Allocation” with publication date: March 16, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>